Welcome to the GLIVEC Product Website

PUBLICATIONS AND PRINTED MATERIALS

Learn more about GLIVEC by viewing, downloading and/or printing the following materials.

Clinical studies with Overviews:

Blay J-Y, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25(9):1107-1113.

VIEW ABSTRACT

DeMatteo RP, Ballman KV, Antonescu CR, et al; for the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097-1104.

VIEW ABSTRACT GO TO OVERVIEW

Learn more about
optimizing
treatment
outcomes

Test your RISK
AWARENESS with
this fun and
challenging activity!

Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J Clin Oncol. 2010;28(7):1247-1253.

VIEW ABSTRACT GO TO OVERVIEW

Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer. 2008;44(4):501-509.

VIEW ABSTRACT GO TO OVERVIEW

Clinical articles of interest:

Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620-625.

VIEW ABSTRACT

Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626-632.

VIEW ABSTRACT

Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST [published online ahead of print May 28, 2010]. Cancer Treat Rev. doi:10.1016/j.ctrv.2010.04.008.

VIEW ABSTRACT

ESMO and NCCN guidelines:

Casali PG, Blay J-Y; for the ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v98-102. To view the most recent and complete version of the guidelines, go online to www.esmo.org/research/esmo-clinical-practice-guidelines.

The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (Version 2.2010). ©2010 National Comprehensive Cancer Network, Inc. http://www.nccn.org. To view the most recent and complete version of the guidelines, go online to www.nccn.org.

Other topics:

Longer adjuvant treatment support

Clinical trials, study designs, adjuvant indication

Multidisciplinary approach brochure

VIDEOS AND ANIMATIONS

Learn more about GLIVEC by viewing the following animation.

See how GLIVEC works in KIT+ GIST.

FAQs about KIT+ GIST
and GLIVEC

Read Now